Background/Objectives: Severe thrombocytopenia (platelet count ≤ 50,000/µL) is a diagnostically heterogeneous condition during pregnancy, encompassing obstetric and non-obstetric etiologies that require distinct management approaches. The aims of this study were to determine the etiological distribution of severe thrombocytopenia during pregnancy and to evaluate its management strategies and perinatal outcomes in a tertiary perinatology center. Methods: This retrospective cohort study included 203 pregnant women with severe thrombocytopenia (platelet count ≤ 50,000/µL) stratified into three groups: Group A (30,000 < platelet count ≤ 50,000/μL, n = 123), Group B (10,000 < platelet count ≤ 30,000/μL, n = 54), and Group C (<10,000/µL, n = 26). Demographic characteristics, etiological diagnoses, treatment modalities, and perinatal outcomes were evaluated. Results: The etiological distribution varied significantly across severity groups (p = 0.001). HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome was the most common cause overall (36.5%) and predominated in milder thrombocytopenia (Group A: 40.7%; Group B: 42.6%), whereas non-obstetric etiologies, such as immune thrombocytopenia (ITP), were significantly more frequent in Group C (57.7%). Treatment intensity increased with severity, with 79.7% of Group A requiring no intervention compared to only 26.9% of Group C (p = 0.001). Gestational age at delivery (median 37 weeks, p = 0.587) and birth weight (mean 2547 ± 968 g, p = 0.191) were comparable across severity groups. Minimum platelet count showed no significant correlation with delivery timing, birth weight, or hemoglobin decline. Conclusions: Severe thrombocytopenia in pregnancy exhibits distinct etiological patterns that vary according to platelet count severity. Favorable perinatal outcomes are achievable with appropriate diagnosis and management in specialized centers, underscoring the importance of comprehensive diagnostic evaluation rather than relying solely on platelet count thresholds for clinical decision-making.

Objective: To investigate the impact of proteinuria severity on obstetric and neonatal outcomes and to assess the predictive value of 24 h urinary protein excretion, both alone and within a multivariable model, for adverse pregnancy outcomes. Methods: This retrospective cohort study included 203 pregnant women with proteinuria who were classified into mild (≥0.3 g/day and <3.0 g/day, n = 50), severe (≥3.0 g/day and <5.0 g/day, n = 67), and massive (≥5.0 g/day; n = 86) groups based on 24 h urine protein levels. Maternal and neonatal outcomes were compared between these groups. Correlation analysis, receiver operating characteristic (ROC) curve analysis, and multivariable logistic regression were used to evaluate the predictive value of proteinuria for obstetric complications and identification of increased risk of early delivery. The AUC values of the proteinuria-only model and the multivariable model were compared using the DeLong test, as both models were derived from the same dataset and therefore represented correlated ROC curves. Results: The incidence of obstetric complications was significantly higher in the severe (68.7%) and massive (81.4%) proteinuria groups compared with the mild group (32.0%; p < 0.001). Increasing proteinuria severity was associated with earlier gestational age at delivery, lower birth weight, and higher rates of fetal growth restriction (all p < 0.001). The 24 h proteinuria level demonstrated moderate predictive ability for obstetric complications (AUC 0.73; 95% CI 0.66–0.80). A multivariable model including nephrotic-range proteinuria (≥3 g/day) and gestational age at diagnosis showed improved discriminatory performance compared with proteinuria alone (AUC 0.81; 95% CI 0.75–0.88). The model based on continuous 24 h proteinuria yielded an AUC of 0.73 (95% CI, 0.66–0.80) for identifying pregnancies at increased risk of obstetric complications. The multivariable model showed a numerically higher AUC of 0.81 (95% CI, 0.73–0.86); however, the difference between the two AUCs was not statistically significant according to the DeLong test (z = 0.82, p = 0.41). Conclusions: The severity of maternal proteinuria is associated with a higher likelihood of adverse maternal and neonatal outcomes, and higher proteinuria levels appear to show a graded association with increasing risk. A multivariable model integrating proteinuria with key clinical parameters demonstrated moderate discriminatory ability for obstetric complications, may support a more holistic approach to risk stratification in clinical practice.

Aims: To compare serum levels of sC5b-9, C3, C4, C1-INH, and CH50, which are indicators of complement system activation and regulatory processes, in pregnant women with and without fetal growth restriction (FGR). Methods: This study enrolled eighty-six women with gestational age between 24 and 36 weeks. Maternal blood samples were obtained from 43 patients diagnosed with FGR and 43 from healthy pregnancies. Serum complement levels were measured using commercially available ELISA kits according to the manufacturer’s instructions (SunRed, China). Results: When the levels of complement activation biomarkers of pregnancies with FGR were compared with those of healthy pregnancies, the C1est level was significantly higher, C4 and CH50 levels were slightly lower, and Sc5b9 and C3 levels were similar. Conclusion: While the exact role of complement activation in FGR remains fully elucidated, the elevated levels of C1-INH in women with FGR suggest a compensatory mechanism to mitigate thrombus formation and inflammation. This adaptive response may be a potential therapeutic target for improving placental function and pregnancy outcomes.

Objective: This study aims to assess Bisphenol-A levels in serum samples from preeclampsia patients and determine potential distinctions by comparing them against samples from healthy pregnant women Material-Methods: This single-center prospective case-control study aimed to investigate the potential differences in serum Bisphenol-A (BPA) levels between pregnant patients diagnosed with preeclampsia and healthy pregnant women. The study encompassed two distinct groups: the study group consisted of 30 pregnant patients diagnosed with preeclampsia, while the control group included 30 healthy pregnant women matched in terms of gestational weeks and demographic characteristics, maintaining a 1:1 ratio. Serum samples were subjected to analysis using a BPA ELISA kit Results: The study encompassed a total of 60 patients, who were categorized into two groups: preeclampsia (n=30) and control (n=30). Upon comparison of the BPA values between the two groups, no statistically significant difference was detected (p=0.579). Conclusion: Clear-cut scientific evidence establishing a conclusive causal link between BPA and preeclampsia is still lacking. Further research is needed in this area

Agenesis of the corpus callosum (ACC) is one of the most common structural brain malformations, with a highly variable prognosis. The aim of this study was